Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells.

ABSTRACT:

Background

Dendritic cell (DC)-mediated antigen presentation is essential for the priming and activation of tumor-specific T cells. However, few drugs that specifically manipulate DC functions are available. The identification of drugs targeting DC holds great promise for cancer immunotherapy.

Methods

We observed that type 1 conventional DCs (cDC1s) initiated a distinct transcriptional program during antigen presentation. We used a network-based approach to screen for cDC1-targeting therapeutics. The antitumor potency and underlying mechanisms of the candidate drug were investigated in vitro and in vivo.

Results

Sitagliptin, an oral gliptin widely used for type 2 diabetes, was identified as a drug that targets DCs. In mouse models, sitagliptin inhibited tumor growth b

SUBMITTER: Ng II 

PROVIDER: S-EPMC10921530 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature